目的 观察丹参注射液与依达拉奉右莰醇在急性脑梗死中的联用效果。方法 选取2021年10月—2024年9月巴彦淖尔市医院收治的122例急性脑梗死患者的病例资料进行回顾性分析，随机分为对照组和治疗组，每组各61例。对照组静脉滴注依达拉奉右莰醇注射用浓溶液，15 mL/次，溶于100 mL的生理盐水，滴注时间＜30 min，2次/d。在对照组基础上，治疗组静脉滴注丹参注射液，20 mL/次，溶于250 mL的生理盐水，1次/d。两组患者连续用药14 d。观察两组患者临床疗效，比较治疗前后两组患者美国国立卫生研究院卒中量表（NIHSS）、Fugl-Meyer上肢运动功能评定量表（U-FMA）和简版脑卒中患者专门生存质量量表（SV-SS-QoL）评分，及搏动指数（PI）、阻力指数（RI）、平均血流速度（V_m）、收缩期峰值血流速度（V_s）、平均血小板体积/血小板计数比值（MPV/PLT）、红细胞分布宽度变异系数（RDW-CV）和C反应蛋白（CRP）水平。结果 治疗后，对照组总有效率为83.61%，治疗组为95.08%，两组患者比较差异具有统计学意义（P＜0.05）。治疗后，两组NIHSS评分显著降低，而U-FMA和SV-SS-QoL评分显著升高（P＜0.05），且治疗组NIHSS、U-FMA和SV-SS-QoL评分明显好于对照组（P＜0.05）。治疗后，两组患者患侧大脑中动脉的PI、RI、MPV/PLT、RDW-CV和CRP均低于同组治疗前，而V_m、V_s则显著升高（P＜0.05），且治疗组这些指标明显均好于对照组（P＜0.05）。结论 丹参注射液联合依达拉奉右莰醇治疗急性脑梗死能有效控制脑血流动力学异常和炎症反应，抑制血栓形成，降低神经功能损害，促进肢体运动功能恢复。

Objective To observe the combined effect of Danshen Injection and edaravone dexmedetomidine in acute cerebral infarction. Methods The clinical data of patients (122 cases) with acute cerebral infarction in Bayannur Hospital from October 2021 to September 2024 were analyzed retrospectively, and they were randomly divided into control and treatment group, each group had 61 cases. Patient in the control group were iv administered with Edaravone and Dexborneol Concentrated Solution for injection, 15 mL/time was added into normal saline 100 mL, the treatment time was less than 30 min, twice daily. Patient in the treatment group were iv administered with Danshen Injection on the basis of the control group, 20 mL/time was added into normal saline 250 mL, once daily. Patient in two groups were treated for 14 d. After treatment, the clinical evaluations were evaluated, and the scores of NIHSS, U-FMA and SV-SS-QoL, and the levels of PI, RI, V_m, V_s, MPV/PLT, RDW-CV and CRP in two groups before and after treatment were compared. Results After treatment, the total effective rate was 83.61% in the control group and 95.08% in the treatment group, the difference between the two groups was statistically significant (P < 0.05). After treatment, the NIHSS scores in two groups were significantly decreased, while the U-FMA and SV-SS-QoL scores were significantly increased (P < 0.05), and these scores in the treatment group were significantly better than those in the control group (P < 0.05). After treatment, PI, RI, MPV/PLT, RDW-CV and CRP in the affected middle cerebral artery in two groups were lower than before treatment, while V_m and V_s were significantly increased (P < 0.05), and these indicators in the treatment group were significantly better than those in the control group (P < 0.05). Conclusion Edaravone and dexmedetomidine combined with Danshen Injection in treatment of acute cerebral infarction can effectively control cerebral hemodynamic abnormalities and inflammatory reactions, inhibit thrombosis, reduce neurological damage, and promote the recovery of limb motor function.

R971

巴彦淖尔市医院科技创新激励计划项目（2023002）